Nielsen, David A. http://orcid.org/0000-0002-2583-0233
Walker, Robrina
Graham, David P.
Nielsen, Ellen M.
Hamon, Sara C.
Hillhouse, Maureen
Shmueli-Blumberg, Dikla
Lawson, William B.
Shores-Wilson, Kathy
Settles-Reaves, Beverlyn D.
Rotrosen, John
Trivedi, Madhukar H.
Saxon, Andrew J.
Ling, Walter
Kosten, Thomas R.
Funding for this research was provided by:
National Institute on Drug Abuse (DA020024, DA018197, DA013045, DA013035, DA013046, DA015815)
National Institutes of Health (DA026120)
Toomim Family Fund
Article History
Received: 18 February 2021
Accepted: 20 February 2022
First Online: 26 February 2022
Declarations
:
: The parent study and genetic sub-study were approved by the Institutional Review Boards of the participating sites as well as by the Institutional Review Board of the Baylor College of Medicine and the Research and Development Committee of the Michael E. DeBakey Veterans Affairs Medical Center.
: Drs. Nielsen, Graham, Hamon, Hillhouse, Shmueli-Blumberg, Lawson, Shores-Wilson, Settles-Reaves, Rotrosen, Ling and Kosten, and Nielsen declare no potential conflict of interest. Drs. Rotrosen, Walker, and Trivedi have served as PI or co-I on studies for which Reckitt Benckiser Pharmaceuticals/Indivior and/or Alkermes have contributed funds, medication, or both. Dr. Trivedi has received compensation as a member of the scientific advisory board of Alkermes Pharmaceuticals and owns stock in the company. Dr. Saxon received compensation as an advisory board member to Alkermes Pharmaceuticals and also received travel support from Alkermes as well as royalties from UpToDate, Inc. and research support from Medicasafe, Inc.